Atrial Septal Articles & Analysis
6 news found
atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced it has received approval for the start of the second phase of its ASCENT ASD U.S. ...
V-Wave shunt has been designated by FDA as a Breakthrough device technology and is uniquely designed to reduce left atrial pressure while minimizing thromboembolic events that have historically seen atrial septal defects. Episodic elevations of left atrial pressure cause worsening symptoms of difficulty breathing often resulting ...
atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the appointment of Andrew Cleeland to the company’s Board of Directors. ...
atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the successful treatment of the first five patients in its ASCENT ASD U.S. ...
atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), announced today that it has commenced operations and is initiating its U.S. ...
I couldn’t be more enthusiastic about our purpose at atHeart Medical: allowing more future options for patients with atrial septal defects (ASDs) by reducing device footprint. Our first product, the reSept ASD Occluder, is the first occluder with a metal-free, bioresorbable frame. ...